BioSpace News Archive

Business

Lilly Reports First-Quarter 2023 Financial Results, Highlights Continued Core Business Growth and Pipeline Momentum

Lilly defines New Products as select products launched since 2022, which currently consist of Jaypirca and Mounjaro.

April 27, 2023

·

22 min read

Business

ANI Pharmaceuticals to Discuss First Quarter 2023 Financial Results on May 8, 2023, at 8:30 a.m. ET

ANI Pharmaceuticals, Inc. today announced that the Company will release its first quarter 2023 financial results on Monday, May 8, 2023, prior to the market open.

April 27, 2023

·

1 min read

Pharm Country

Intercept Announces New Data to be Presented at The European Association for the Study of the Liver (EASL) Congress 2023 and Provides Update on OCA-bezafibrate Fixed-Dose Combination (FDC) Development Program

Intercept Pharmaceuticals, Inc. announced that seven abstracts in PBC and NASH have been accepted for presentation at EASL 2023.

April 27, 2023

·

15 min read

Business

Apellis Pharmaceuticals to Host Conference Call on May 4, 2023, to Discuss First Quarter 2023 Financial Results

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will host a conference call and webcast to discuss its first quarter 2023 financial results on Thursday, May 4, 2023, at 4:30 p.m. ET.

April 27, 2023

·

1 min read

Business

Intercept Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Update on Commercial Launch Strategy for NASH

Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, announced its financial results for the quarter ended on March 31, 2023.

April 27, 2023

·

27 min read

BioMidwest

Clearside Biomedical Presents Compelling Data at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

Clearside Biomedical, Inc. announced that several key poster presentations were delivered on the Company’s suprachoroidal injection delivery platform at The Association for Research in Vision and Ophthalmology 2023 Annual Meeting.

April 27, 2023

·

13 min read

Drug Development

4DMT Presents Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ARVO 2023

4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company) today announced positive interim clinical data from the Phase 1 Dose Exploration stage (three doses, n=15) of the 4D-150 Phase 1/2 PRISM clinical trial for wet age-related macular degeneration (wet AMD).

April 27, 2023

·

11 min read

Business

PROCEPT BioRobotics Reports First Quarter 2023 Financial Results and Increases 2023 Revenue Guidance

PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2023.

April 27, 2023

·

11 min read

Cell Manufacturing Pioneer, Pluri Inc., Unveils PluriMatrix: a Breakthrough System for Unprecedented Industrial Scale Production of Cell-Based Products

Pluri Inc., a leading biotech company that transforms cells into solutions that promote wellbeing and sustainability, unveiled a breakthrough in cell manufacturing that potentially solves one of the biggest hurdles facing cell-based industries: cost-effective, industrial scale cell manufacturing.

April 27, 2023

·

6 min read

Compugen to Present New Clinical Data Showing Preliminary Anti-Tumor Activity of COM701 Triple Combination in Recurrent MSS-Metastatic Endometrial Cancer at ASCO 2023

Compugen Ltd. today announced that it will present new clinical data on COM701 in triple combination with BMS-986207 (anti-TIGIT) and nivolumab in metastatic endometrial cancer at the American Society of Clinical Oncology (ASCO) annual meeting on June 2-6, 2023, in Chicago, Illinois.

April 27, 2023

·

2 min read